首页> 美国卫生研究院文献>other >Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells
【2h】

Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells

机译:组织蛋白酶对抑制剂诱导的反馈的不同反应:E-64和胱抑素C升高乳腺癌组织中的活跃组织蛋白酶S并抑制活跃的组织蛋白酶L

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cathepsins are powerful proteases, once referred to as the lysosomal cysteine proteases, that have been implicated in breast cancer invasion and metastasis, but pharmaceutical inhibitors have suffered failures in clinical trials due to adverse side effects. Scientific advancement from lysosomotropic to cell impermeable cathepsin inhibitors have improved efficacy in treating disease, but off-target effects have still been problematic, motivating a need to better understand cellular feedback and responses to treatment with cathepsin inhibitors. To address this need, we investigated effects of E-64 and cystatin C, two broad spectrum cathepsin inhibitors, on cathepsin levels intra- and extracellularly in MDA-MB-231 breast cancer cells. Cathepsins S and L had opposing responses to both E-64 and cystatin C inhibitor treatments with paradoxically elevated amounts of active cathepsin S, but decreased amounts of active cathepsin L, as determined by multiplex cathepsin zymography. This indicated cellular feedback to selectively sustain the amounts of active cathepsin S even in the presence of inhibitors with subnanomolar inhibitory constant values. These differences were identified in cellular locations of cathepsins L and S, trafficking for secretion, co-localization with endocytosed inhibitors, and longer protein turnover time for cathepsin S compared to cathepsin L. Together, this work demonstrates that previously underappreciated cellular compensation and compartmentalization mechanisms may sustain elevated amounts of some active cathepsins while diminishing others after inhibitor treatment. This can confound predictions based solely on inhibitor kinetics, and must be better understood to effectively deploy therapies and dosing strategies that target cathepsins to prevent cancer progression.
机译:组织蛋白酶是强大的蛋白酶,曾经被称为溶酶体半胱氨酸蛋白酶,与乳腺癌的侵袭和转移有关,但是由于不良副作用,药物抑制剂在临床试验中失败了。从溶血同质性向细胞不可渗透的组织蛋白酶抑制剂的科学进展提高了治疗疾病的功效,但脱靶效应仍然存在问题,激发了对更好地了解细胞反馈和对组织蛋白酶抑制剂治疗反应的需求。为了满足这一需求,我们研究了两种广谱组织蛋白酶抑制剂E-64和cystatin C对MDA-MB-231乳腺癌细胞内和细胞外组织蛋白酶水平的影响。组织蛋白酶S和L对E-64和胱抑素C抑制剂的治疗均具有相反的反应,其活性组织蛋白酶S的含量反常升高,但活性组织蛋白酶L的含量却降低了,这是由多重组织蛋白酶酶谱确定的。这表明细胞反馈即使在存在具有亚纳摩尔抑制常数的抑制剂的情况下也能选择性维持活性组织蛋白酶S的量。与组织蛋白酶L相比,在组织蛋白酶L和S的细胞位置,运输的分泌,与胞吞抑制剂的共定位以及组织蛋白酶S的蛋白质周转时间更长的方面,已经确定了这些差异。在一起,这项工作证明了以前对细胞的补偿和分隔机制的认识不足。抑制剂治疗后可能会维持某些活性组织蛋白酶的升高水平,同时减少其他活性。这可以混淆仅基于抑制剂动力学的预测,并且必须更好地理解以有效地部署针对组织蛋白酶的疗法和剂量策略,以防止癌症进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号